Theoretical assessment of a new experimental protocol for determining kinetic values describing mechanism (time)-based enzyme inhibition

European Journal of Pharmaceutical Sciences

Volumn 31, Issue 3-4, 2007, Pages 232-241

  Yang, Jiansong ^a   Jamei, Masoud ^a   Yeo, Karen Rowland ^a   Tucker, Geoffrey T ^a,b   Rostami Hodjegan, Amin ^a,b  

^a CERTARA UK LIMITED   (United Kingdom)

^b UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Drug interactions; Enzyme inactivation; Genetic algorithm; Mechanism based inhibition; Simulation

Indexed keywords

1 [(2 ETHYL 4 METHYL 1H IMIDAZOL 5 YL)METHYL] 4 [4 (TRIFLUOROMETHYL) 2 PYRIDINYL]PIPERAZINE; 2 PHENYL 2 (1 PIPERIDINYL)PROPANE; BENZAMIDE DERIVATIVE; CYTOCHROME P450; DELAVIRDINE; DILTIAZEM; ETHINYLESTRADIOL; GESTODENE; L 754394; MENTHOFURAN; MIBEFRADIL; N (2 HYDROXY 1 INDANYL) 5 [2 (1,1 DIMETHYLETHYLAMINOCARBONYL)] 4 [(FURO[2,3 B]PYRIDIN 5 YL)METHYLPIPERAZIN 1 YL] 4 HYDROXY 2 PHENYLMETHYLPENTANAMIDE; N (3,5 DICHLORO 4 PYRIDYL) 4 METHOXY 3 (PROP 2 YNYLOXY)BENZAMIDE; PHENCYCLIDINE; PIPERAZINE DERIVATIVE; PIPERIDINE DERIVATIVE; SUPROFEN; THIOTEPA; TICLOPIDINE; UNCLASSIFIED DRUG; VERAPAMIL;

ACCURACY; ARTICLE; COMPETITIVE INHIBITION; COMPUTER SIMULATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME INHIBITION; GENETIC ALGORITHM; IN VITRO STUDY; IN VIVO STUDY; MECHANISM BASED ENZYME INHIBITION; MECHANISTICALLY BASED EXPERIMENTAL PROTOCOL; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROCESS OPTIMIZATION; QUANTITATIVE ANALYSIS; STATISTICAL PARAMETERS; THEORETICAL STUDY; TIME;

ALGORITHMS; COMPUTER SIMULATION; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; ENZYMES; HUMANS; KINETICS; MODELS, CHEMICAL; PHARMACEUTICAL PREPARATIONS;

EID: 34249274907     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2007.04.005     Document Type: Article

References (49)

1. Atkinson A., Kenny J.R., and Grime K. Automated assessment of time-dependent inhibition of human cytochrome P450 enzymes using liquid chromatography-tandem mass spectrometry analysis. Drug Metab. Dispos. 33 (2005) 1637-1647
2. Bertelsen K.M., Venkatakrishnan K., von Moltke L.L., Obach R.S., and Greenblatt D.J. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metab. Dispos. 31 (2003) 289-293
3. Bies R.R., Muldoon M.F., Pollock B.G., Manuck S., Smith G., and Sale M.E. A genetic algorithm-based, hybrid machine learning approach to model selection. J. Pharmacokinet. Pharmacodyn. 33 (2006) 195-221
4. Bjornsson T.D., Callaghan J.T., Einolf H.J., Fischer V., Gan L., Grimm S., Kao J., King S.P., Miwa G., Ni L., Kumar G., McLeod J., Obach R.S., Roberts S., Roe A., Shah A., Snikeris F., Sullivan J.T., Tweedie D., Vega J.M., Walsh J., and Wrighton S.A. The conduct of in vitro and in vivo drug-drug interaction studies: a pharmaceutical research and manufacturers of America (PhRMA) perspective. Drug Metab. Dispos. 31 (2003) 815-832
5. Chen X.Q., Cho S.J., Li Y., and Venkatesh S. Prediction of aqueous solubility of organic compounds using a quantitative structure-property relationship. J. Pharm. Sci. 91 (2002) 1838-1852
6. Chiba M., Nishime J.A., and Lin J.H. Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. J. Pharmacol. Exp. Ther. 275 (1995) 1527-1534
7. Chun J., Kent U.M., Moss R.M., Sayre L.M., and Hollenberg P.F. Mechanism-based inactivation of cytochromes P4502B1 and P4502B6 by 2-phenyl-2-(1-piperidinyl) propane. Drug Metab. Dispos. 28 (2000) 905-911
8. Fan P.W., Gu C., Marsh S.A., and Stevens J.C. Mechanism-based inactivation of cytochrome P450 2B6 by a novel terminal acetylene inhibitor. Drug Metab. Dispos. 31 (2003) 28-36
9. Favreau L.V., Palamanda J.R., Lin C.-c., and Nomeir A.A. Improved reliability of the rapid microtiter plate assay using recombinant enzyme in predicting CYP2D6 inhibition in human liver microsomes. Drug Metab. Dispos. 27 (1999) 436-439
10. FDA, 2006. Guidance for industry: drug interaction studies - study design, data analysis, and implications for dosing and labeling.
11. Ghanbari F., Rowland-Yeo K., Bloomer J.C., Clarke S.E., Lennard M.S., Tucker G.T., and Rostami-Hodjegan A. A critical evaluation of the experimental design of studies of mechanism based enzyme inhibition, with implications for in vitro-in vivo extrapolation. Curr. Drug Metab. 7 (2006) 315-334
12. Goldberg D.E. Genetic Algorithms in Search, Optimisation, and Machine Learning (1989), Addison-Wesley, Wokingham
13. Guengerich F.P. Mechanism-based inactivation of human liver microsomal cytochrome P-450 IIIA4 by gestodene. Chem. Res. Toxicol. 3 (1990) 363-371
14. Ha-Duong N.T., Dijols S., Macherey A.C., Dansette P.M., and Mansuy D. Inhibition by ticlopidine and its derivatives of human liver cytochrome P450. Mechanism-based inactivation of CYP2C19 by ticlopidine. Biol. React. Intermed. Vi (2001) 145-148
15. Harleton E., Webster M., Bumpus N.N., Kent U.M., Rae J.M., and Hollenberg P.F. Metabolism of N,N',N"-triethylenethiophosphoramide by CYP2B1 and CYP2B6 results in the inactivation of both isoforms by two distinct mechanisms. J. Pharmacol. Exp. Ther. 310 (2004) 1011-1019
16. Hollenberg P.F. Characteristics and common properties of inhibitors, inducers, and activators of CYP enzymes. Drug Metab. Rev. 34 (2002) 17-35
17. Hutzler J.M., Steenwyk R.C., Smith E.B., Walker G.S., and Wienkers L.C. Mechanism-based inactivation of cytochrome P450 2D6 by 1-[(2-ethyl-4-methyl-1H-imidazol-5-yl)methyl]-4-[4-(trifluoromethyl)-2-p yridinyl]piperazine: kinetic characterization and evidence for apoprotein adduction. Chem. Res. Toxicol. 17 (2004) 174-184
18. Ito K., Iwatsubo T., Kanamitsu S., Ueda K., Suzuki H., and Sugiyama Y. Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver. Pharmacol. Rev. 50 (1998) 387-412
19. Jones D.R., Gorski J.C., Hamman M.A., Mayhew B.S., Rider S., and Hall S.D. Diltiazem inhibition of cytochrome P-450 3A activity is due to metabolite intermediate complex formation. J. Pharmacol. Exp. Ther. 290 (1999) 1116-1125
20. Jones H.M., and Houston J.B. Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos. 32 (2004) 973-982
21. Jushchyshyn M.I., Kent U.M., and Hollenberg P.F. The mechanism-based inactivation of human cytochrome P4502B6 by phencyclidine. Drug Metab. Dispos. 31 (2003) 46-52
22. Kent U.M., Mills D.E., Rajnarayanan R.V., Alworth W.L., and Hollenberg P.F. Effect of 17-alpha-ethynylestradiol on activities of cytochrome P4502B (P450 2B) enzymes: characterization of inactivation of P450s 2B1 and 2B6 and identification of metabolites. J. Pharmacol. Exp. Ther. 300 (2002) 549-558
23. Khojasteh-Bakht S.C., Koenigs L.L., Peter R.M., Trager W.F., and Nelson S.D. (R)-(+)-menthofuran is a potent, mechanism-based inactivator of human liver cytochrome P450 2A6. Drug Metab. Dispos. 26 (1998) 701-704
24. Kitz R., and Wilson I.B. Esters of methanesulfonic acid as irreversible inhibitiors of acetylcholinesterase. J. Biol. Chem. 237 (1962) 3245-3249
25. Lin H.L., Kent U.M., and Hollenberg P.F. Mechanism-based inactivation of cytochrome P450 3A4 by 17 alpha-ethynylestradiol: evidence for heme destruction and covalent binding to protein. J. Pharmacol. Exp. Ther. 301 (2002) 160-167
26. Lin J.H., and Lu A.Y. Inhibition and induction of cytochrome P450 and the clinical implications. Clin. Pharmacokinet. 35 (1998) 361-390
27. Maurer T., and Fung H.L. Comparison of methods for analyzing kinetic data from mechanism-based enzyme inactivation: application to nitric oxide synthase. AAPS PharmSci. 2 (2000) E8
28. Mayhew B.S., Jones D.R., and Hall S.D. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab. Dispos. 28 (2000) 1031-1037
29. O'Donnell J.P., Dalvie D.K., Kalgutkar A.S., and Obach R.S. Mechanism-based inactivation of human recombinant P4502C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab. Dispos. 31 (2003) 1369-1377
30. Obach R.S., and Reed-Hagen A.E. Measurement of Michaelis constants for cytochrome P450-mediated biotransformation reactions using a substrate depletion approach. Drug Metab. Dispos. 30 (2002) 831-837
31. Paine M.F., Criss A.B., and Watkins P.B. Two major grapefruit juice components differ in intestinal CYP3A4 inhibition kinetic and binding properties. Drug Metab. Dispos. 32 (2004) 1146-1153
32. Prueksaritanont T., Ma B., Tang C.Y., Meng Y., Assang C., Lu P., Reider P.J., Lin J.H., and Baillie T.A. Metabolic interactions between mibefradil and HMG-CoA reductase inhibitors: an in vitro investigation with human liver preparations. Br. J. Clin. Pharmacol. 47 (1999) 291-298
33. Pumford N.R., and Halmes N.C. Protein targets of xenobiotic reactive intermediates. Annu. Rev. Pharmacol. Toxicol. 37 (1997) 91-117
34. Rytting E., Lentz K.A., Chen X.Q., Qian F., and Venkatesh S. A quantitative structure-property relationship for predicting drug solubility in PEG 400/water cosolvent systems. Pharm. Res. 21 (2004) 237-244
35. Silverman R.B. Mechanism-Based Enzyme Inactivation: Chemistry and Enzymology (1988), CRC Press, Boca Raton
36. Silverman R.B. Mechanism-based enzyme inactivators. Meth. Enzymol. 249 (1995) 240-283
37. Tatsunami S., Yago N., and Hosoe M. Kinetics of suicide substrates. Steady-state treatments and computer-aided exact solutions. Biochim. Biophys. Acta 662 (1981) 226-235
38. Venkatakrishnan K., von Moltke L.L., Obach R.S., and Greenblatt D.J. Drug metabolism and drug interactions: application and clinical value of in vitro models. Curr. Drug Metab. 4 (2003) 423-459
39. von Moltke L.L., Durol A.L.B., Duan S.X., and Greenblatt D.J. Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole. Eur. J. Clin. Pharmacol. 56 (2000) 259-261
40. Voorman R.L., Maio S.M., Payne N.A., Zha Z.Y., Koeplinger K.A., and Wang X.H. Microsomal metabolism of delavirdine: evidence for mechanism-based inactivation of human cytochrome p450 3A. J. Pharmacol. Exp. Ther. 287 (1998) 381-388
41. Voorman R.L., Payne N.A., Wienkers L.C., Hauer M.J., and Sanders P.E. Interaction of delavirdine with human liver microsomal cytochrome P450: inhibition of CYP2C9, CYP2C19, and CYP2D6. Drug Metab. Dispos. 29 (2001) 41-47
42. Waley S.G. Kinetics of suicide substrates. Biochem. J. 185 (1980) 771-773
43. Walsh C., Cromartie T., Mariotte P., and Spencer R. Suicide substrates for flavoprotein enzymes. Meth. Enzymol. 53 (1978) 437-448
44. Walsky R.L., and Obach R.S. Validated assays for human cytochrome P450 activities. Drug Metab. Dispos. 32 (2004) 647-660
45. Yamashita F., Wanchana S., and Hashida M. Quantitative structure/property relationship analysis of Caco-2 permeability using a genetic algorithm-based partial least squares method. J. Pharm. Sci. 91 (2002) 2230-2239
46. Yang J., Jamei M., Heydari A., Yeo K., De La Torre R., Farre M., Tucker G.T., and Rostami-Hodjegan A. Implications of mechanism-based inhibition of CYP2D6 for the pharmacokinetics and toxicity of MDMA. J. Psychopharmacol. 20 (2006) 842-849
47. Yang J., Jamei M., Yeo K.R., Rostami-Hodjegan A., and Tucker G.T. Kinetic values for mechanism-based inhibition: assessment of bias introduced by the conventional experimental protocol. Eur. J. Pharm. Sci. 26 (2005) 334-340
48. Yeo K.R., and Yeo W.W. Inhibitory effects of verapamil and diltiazem on simvastatin metabolism in human liver microsomes. Br. J. Clin. Pharmacol. 51 (2001) 461-470
49. Zhou S.F., Chan S.Y., Goh B.C., Chan E., Duan W., Huang M., and McLeod H.L. Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs. Clin. Pharmacokinet. 44 (2005) 279-304